PD-1/PD-L1 immune checkpoint inhibitors have revolutionized oncology. Now, many cancer patients who would have rapidly died of their cancer enjoy durable remissions with excellent quality of life. Unfortunately, these therapies only benefit a minority of patients. We are studying a cancer of children, adolescents and young adults called synovial sarcoma. This is an immunologically "cold" tumor that is almost never controlled by PD-1 pathway inhibitors, despite consistent and homogenous expression of immunogenic antigens. Our data suggest that systemic interferon gamma, an FDA approved drug, can transform the sarcoma microenvironment, making it "hot," with increased expression of antigen-presenting major histocompatibility complex (MHC) proteins and increased T cell infiltration, and increased PD-L1 expression on tumor. We hypothesize that interferon gamma thereby makes synovial sarcoma susceptible to PD-1 blockade. In the proposed project, we will combine interferon gamma and PD-1-blocking pembrolizumab in a clinical trial aimed at eradicating synovial sarcoma. Tumor biopsies will be collected and multiplex immunohistochemistry performed to quantitate tumor MHC expression and T cell infiltrates, and to characterize other components of the tumor microenvironment that can determine the efficacy of immune responses. We will use T cell receptor (TCR) sequencing to characterize T cell abundance and clonality. From some patients, single cell suspensions will be prepared for flow cytometry, gene expression analysis and single cell TCR/RNA sequencing of sorted populations. We anticipate our findings will identify novel therapeutic targets and thereby inform subsequent trials that can help bring clinical benefit to more patients.
|Effective start/end date||7/15/21 → 11/1/22|
- V Foundation for Cancer Research (T2018-006B)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.